Literature DB >> 30506145

Alport syndrome: deducing the mode of inheritance from the presence of haematuria in family members.

Judy Savige1.   

Abstract

The diagnosis of Alport syndrome is suspected when an individual has haematuria or renal failure, together with a hearing loss; haematuria or renal failure, and a family history of Alport syndrome; or a pathognomonic Alport feature, such as lenticonus, fleck retinopathy, a lamellated glomerular basement membrane (GBM), or a GBM that lacks the collagen IV α3α4α5 network. The diagnosis of Alport syndrome is optimally confirmed by the demonstration of a mutation in the COL4A5 gene or two mutations in trans in the COL4A3 or COL4A4 genes. In practice, genetic testing for Alport syndrome is not widely available, and even with testing, causative mutations are not demonstrated in 5% of cases. Often, haematuria is only known in some family members, and the other characteristic features are not present or have not been sought. Where Alport syndrome remains likely, it is important to distinguish between X-linked inheritance, which occurs in 85% of families, and autosomal recessive inheritance, in the remaining 15%. This distinction is important because different modes of inheritance mean that different family members are at risk of being affected. Clinicians generally rely on the presence of haematuria to identify affected individuals in families with suspected Alport syndrome and on the information from three-generational family trees to assess the likely mode of inheritance. While often helpful, this strategy can also be misleading. The major sources of error are families with few members or where few members are tested; families comprising mainly women, where the typical Alport features are absent; families where the father is not available for testing for haematuria; and families with a coincidental renal disease. These difficulties emphasise the helpfulness of genetic testing in distinguishing between X-linked and autosomal recessively inherited forms of Alport syndrome.

Entities:  

Keywords:  Alport syndrome; COL4A5 mutations; Genetic testing; Glomerular basement membrane; Next-generation sequencing; Pedigree analysis; Thin basement membrane nephropathy

Year:  2018        PMID: 30506145     DOI: 10.1007/s00467-018-4121-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  28 in total

1.  COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome.

Authors:  Helen Storey; Judy Savige; Vanessa Sivakumar; Stephen Abbs; Frances A Flinter
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

2.  Alport's syndrome: experience at Hôpital Necker.

Authors:  R Habib; M C Gubler; N Hinglais; L H Noël; D Droz; M Levy; P Mahieu; J M Foidart; D Perrin; E Bois; J P Grünfeld
Journal:  Kidney Int Suppl       Date:  1982-05       Impact factor: 10.545

3.  X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.

Authors:  Jean Philippe Jais; Bertrand Knebelmann; Iannis Giatras; Mario DE Marchi; Gianfranco Rizzoni; Alessandra Renieri; Manfred Weber; Oliver Gross; Kai-Olaf Netzer; Frances Flinter; Yves Pirson; Christine Verellen; Jörgen Wieslander; Ulf Persson; Karl Tryggvason; Paula Martin; Jens Michael Hertz; Cornelis Schröder; Marek Sanak; Sarka Krejcova; Maria Fernanda Carvalho; Juan Saus; Corinne Antignac; Hubert Smeets; Marie Claire Gubler
Journal:  J Am Soc Nephrol       Date:  2000-04       Impact factor: 10.121

4.  Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain.

Authors:  Yuya Hashimura; Kandai Nozu; Hiroshi Kaito; Koichi Nakanishi; Xue Jun Fu; Hiromi Ohtsubo; Fusako Hashimoto; Masafumi Oka; Takeshi Ninchoji; Shingo Ishimori; Naoya Morisada; Natsuki Matsunoshita; Naohiro Kamiyoshi; Norishige Yoshikawa; Kazumoto Iijima
Journal:  Kidney Int       Date:  2013-12-04       Impact factor: 10.612

5.  Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis.

Authors:  Christine Gast; Reuben J Pengelly; Matthew Lyon; David J Bunyan; Eleanor G Seaby; Nikki Graham; Gopalakrishnan Venkat-Raman; Sarah Ennis
Journal:  Nephrol Dial Transplant       Date:  2015-09-07       Impact factor: 5.992

6.  Temporal macular thinning associated with X-linked Alport syndrome.

Authors:  Faisal Ahmed; Kandon K Kamae; Denise J Jones; Margaret M Deangelis; Gregory S Hageman; Martin C Gregory; Paul S Bernstein
Journal:  JAMA Ophthalmol       Date:  2013-06       Impact factor: 7.389

Review 7.  Expert consensus guidelines for the genetic diagnosis of Alport syndrome.

Authors:  Judy Savige; Francesca Ariani; Francesca Mari; Mirella Bruttini; Alessandra Renieri; Oliver Gross; Constantinos Deltas; Frances Flinter; Jie Ding; Daniel P Gale; Mato Nagel; Michael Yau; Lev Shagam; Roser Torra; Elisabet Ars; Julia Hoefele; Guido Garosi; Helen Storey
Journal:  Pediatr Nephrol       Date:  2018-07-09       Impact factor: 3.714

8.  Clinical utility gene card for: Alport syndrome - update 2014.

Authors:  Jens Michael Hertz; Mads Thomassen; Helen Storey; Frances Flinter
Journal:  Eur J Hum Genet       Date:  2014-11-12       Impact factor: 4.246

9.  A patient with autosomal recessive Alport syndrome due to segmental maternal isodisomy.

Authors:  Xue J Fu; Naoya Morisada; Fusako Hashimoto; Mariko Taniguchi-Ikeda; Yuya Hashimura; Hiromi Ohtsubo; Takeshi Ninchoji; Hiroshi Kaito; Kandai Nozu; Eihiko Takahashi; Koichi Nakanishi; Hiroki Kurahashi; Kazumoto Iijima
Journal:  Hum Genome Var       Date:  2014-08-07

10.  Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases.

Authors:  C Fallerini; L Dosa; R Tita; D Del Prete; S Feriozzi; G Gai; M Clementi; A La Manna; N Miglietti; R Mancini; G Mandrile; G M Ghiggeri; G Piaggio; F Brancati; L Diano; E Frate; A R Pinciaroli; M Giani; P Castorina; E Bresin; D Giachino; M De Marchi; F Mari; M Bruttini; A Renieri; F Ariani
Journal:  Clin Genet       Date:  2013-10-17       Impact factor: 4.438

View more
  2 in total

1.  Guidelines for Genetic Testing and Management of Alport Syndrome.

Authors:  Judy Savige; Beata S Lipska-Zietkiewicz; Elizabeth Watson; Jens Michael Hertz; Constantinos Deltas; Francesca Mari; Pascale Hilbert; Pavlina Plevova; Peter Byers; Agne Cerkauskaite; Martin Gregory; Rimante Cerkauskiene; Danica Galesic Ljubanovic; Francesca Becherucci; Carmela Errichiello; Laura Massella; Valeria Aiello; Rachel Lennon; Louise Hopkinson; Ania Koziell; Adrian Lungu; Hansjorg Martin Rothe; Julia Hoefele; Miriam Zacchia; Tamara Nikuseva Martic; Asheeta Gupta; Albertien van Eerde; Susie Gear; Samuela Landini; Viviana Palazzo; Laith Al-Rabadi; Kathleen Claes; Anniek Corveleyn; Evelien Van Hoof; Micheel van Geel; Maggie Williams; Emma Ashton; Hendica Belge; Elisabet Ars; Agnieszka Bierzynska; Concetta Gangemi; Alessandra Renieri; Helen Storey; Frances Flinter
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-20       Impact factor: 8.237

2.  Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.

Authors:  Oliver Gross; Jie Ding; Yanqin Zhang; Jan Böckhaus; Fang Wang; Suxia Wang; Diana Rubel
Journal:  Pediatr Nephrol       Date:  2021-03-27       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.